

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
J0717	Certolizumab Pegol Inj 1mg	1 MG	6.561								
J0720	Chloramphenicol sodium injec	1 GM	31.736								
J0725	Chorionic gonadotropin/1000u	1000 UNITS	18.069								
J0735	Clonidine hydrochloride	1 MG	19.165								
J0740	Cidofovir injection	375 MG	588.097								
J0743	Cilastatin sodium injection	250 MG	4.826								
J0744	Ciprofloxacin iv	200 MG	1.097								
J0770	Colistimethate sodium inj	150 MG	11.501								
J0775	Collagenase, clost hist inj	0.01 MG	38.261								
J0780	Prochlorperazine injection	10 MG	9.357								
J0795	Corticorelin ovine triflusal	1 MCG	7.724								
J0800	Corticotropin injection	40 UNITS	3324.923								
J0834	Cosyntropin cortrosyn inj	0.25 MG	51.358								
J0840	Crotalidae poly immune fab	UP TO 1 GM	2493.120								
J0850	Cytomegalovirus imm IV /vial	PER VIAL	1013.869								
J0878	Daptomycin injection	1 MG	0.670								
J0881	Darbepoetin alfa, non-esrd	1 MCG	3.767								
J0882	Darbepoetin alfa, esrd use	1 MCG	3.767								
J0885	Epoetin alfa, non-esrd	1000 UNITS	11.653								
J0886	Epoetin alfa 1000 units ESRD	1000 UNITS	11.653								
J0894	Decitabine injection	1 MG	28.250								
J0895	Deferoxamine mesylate inj	500 MG	8.663		95	15.630					
J0897	Denosumab injection	1 MG	14.446								
J1000	Depo-estradiol cypionate inj	5 MG	10.348								
J1020	Methylprednisolone 20 MG inj	20 MG	3.484								
J1030	Methylprednisolone 40 MG inj	40 MG	3.249								
J1040	Methylprednisolone 80 MG inj	80 MG	6.241								
J1050	Medroxyprogesterone acetate	1 MG	0.280								
J1070	Testosterone cypionat 100 MG	100 MG	4.941								
J1080	Testosterone cypionat 200 MG	200 MG	4.972								
J1100	Dexamethasone sodium phos	1 MG	0.142								
J1110	Inj dihydroergotamine mesylt	1 MG	65.268								
J1120	Acetazolamid sodium injectio	500 MG	22.388								
J1160	Digoxin injection	0.5 MG	5.536								
J1162	Digoxin immune fab (ovine)	PER VIAL	2051.630								
J1165	Phenytoin sodium injection	50 MG	0.530								
J1170	Hydromorphone injection	4 MG	1.834		95	1.490					
J1190	Dexrazoxane HCl injection	250 MG	144.864								
J1200	Diphenhydramine hcl injectio	50 MG	0.534								
J1205	Chlorothiazide sodium inj	500 MG	122.652								
J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	83.539								
J1230	Methadone injection	10 MG	8.495		95	0.750					

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	Vaccine AWP%	Vaccine Limit	Infusion AWP%	DME Infusion Limit	Blood AWP%	Blood limit	Clotting Factor	Notes
J8521	Capecitabine, oral, 500 mg	500 MG	28.631								
J8530	Cyclophosphamide oral 25 MG	25 MG	1.073								
J8540	Oral dexamethasone	0.25 MG	0.195								
J8560	Etoposide oral 50 MG	50 MG	57.087								
J8600	Melphalan oral 2 MG	2 MG	9.416								
J8610	Methotrexate oral 2.5 MG	2.5 MG	1.084								
J8700	Temozolomide	5 MG	5.385								
J8705	Topotecan oral	0.25 mg	94.739								
J9000	Doxorubicin hcl injection	10 MG	3.004								
J9015	Aldesleukin injection	1 EA	2110.630								
J9017	Arsenic trioxide injection	1 MG	53.583								
J9019	Erwinaze injection	1,000 IU	354.755								
J9020	Asparaginase, NOS	10000 UNITS	64.565								
J9025	Azacitidine injection	1 MG	4.083								
J9027	Clofarabine injection	1 MG	134.103								
J9031	Bcg live intravesical vac	1 EA	121.959								
J9033	Bendamustine injection	1 MG	22.212								
J9035	Bevacizumab injection	10 MG	66.653								
J9040	Bleomycin sulfate injection	15 UNITS	20.716			95	289.370				
J9041	Bortezomib injection	0.1 MG	46.081								
J9042	Brentuximab vedotin inj	1 MG	110.820								
J9043	Cabazitaxel injection	1 MG	142.424								
J9045	Carboplatin injection	50 MG	3.454								
J9047	Injection, Carfilzomib, 1 mg	1 MG	29.810								
J9050	Carmustine injection	100 MG	1861.116								
J9055	Cetuximab injection	10 MG	53.287								
J9060	Cisplatin 10 MG injection	10 MG	2.038								
J9065	Inj cladribine per 1 MG	1 MG	21.209			95	61.720				
J9070	Cyclophosphamide 100 MG inj	100 MG	63.159								
J9098	Cytarabine liposome inj	10 MG	561.391								
J9100	Cytarabine hcl 100 MG inj	100 MG	0.935			95	8.190				
J9120	Dactinomycin injection	0.5 MG	807.190								
J9130	Dacarbazine 100 mg inj	100 MG	3.637								
J9150	Daunorubicin injection	10 MG	22.558								
J9155	Degarelix injection	1 MG	3.545								
J9171	Docetaxel injection	1 MG	4.660								
J9178	Inj, epirubicin hcl, 2 mg	2 MG	1.347								
J9179	Eribulin mesylate injection	0.1 MG	99.006								
J9181	Etoposide injection	10 MG	0.680								
J9185	Fludarabine phosphate inj	50 MG	70.981								
J9190	Fluorouracil injection	500 MG	2.057			95	2.070				
J9200	Floxuridine injection	500 MG	55.652			95	136.800				AMP-based payment limit

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Payment Allowance Limits for Medicare Part B Drugs

Effective October 1, 2014 through December 31, 2014

Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q14 ASP data.

Note 2: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.